LTRN | Nirvana Systems Inc.

Tag Archives for " LTRN "

LTRN: Reviving Failed Oncology Drugs with AI

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Initiating Coverage We are initiating coverage of Lantern Pharma Inc., (NASDAQ:LTRN) with a current valuation of $28 per share. Lantern is a new type of drug development company employing artificial intelligence and big data to identify critical biomarkers and relevant indications for previously investigated […]

Continue reading